Macrocure Ltd. (Nasdaq: MCUR) reported disappointing results from a Phase 3 study of CureXcell(R) to treat diabetic foot ulcers sending the stock price plummeting $2.61 to close at $1.65.
Macrocure reports disappointing study results
October 28, 2015 at 19:02 PM EDT
